Chronic infections present a large global health threat and therefore prevention is currently a major focus for reducing disease prevalence. The prevention strategies of vaccination have shown some highly promising results on diseases such as HIV and HSV-1, and the advancement and evolution of vaccine development in VIDD involves an ambitious team of scientists. Basic scientists, computer and animal modelers, statisticians, epidemiologists and clinicians work together throughout this rigorous process, from idea conception to clinical trial design and finally to vaccine production.
Select a letter to display a list of Faculty members
Research interests include sexual risk taking, victimization and alcohol/drug abuse among African-American women, HIV prevention for African American and African-born populations and health disparities.
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infection complications, genome and gene expression studies.
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Statistical and computational methods for bioinformatics applications, statistical modeling for genome sequence analysis and statistical modeling frameworks. The interface between computer science, statistics, and molecular biologyand such as development of new informatics methods in genomics and post-genomics
Computational and statistical methods development for high-throughput, high-content biological data.
Modeling and integration of data from high throughput assays for biomarker discovery, clinical outcome prediction and disease classification.
Current studies include development of methods for T-cell based sieve analysis, quantification of vaccine induced T cell responses, systems biology of influenza and time-dependent correlates analysis of HIV efficacy trial.
Research focus includes vaccine clinical trials, the design and analysis of Phase I/II trials, for evaluating vaccine effects on immune responses; the design and analysis of Phase 2b/III trials, for evaluating vaccine efficacy, immune correlates, sieve analysis, and post-infection vaccine effects; general biostatistical methods research, such as survival analysis, causal inference, and evaluation of surrogate endpoints
Developing methods and tools for high-throughput, high-dimensional experiments with applications in vaccine research, immunology and immunotherapy; flow cytometry, peptide microarrays, next generation sequencing; Bayesian inference and computation and statistical computing
Design, conduct, monitoring, and analysis of multicenter randomized clinical trials and comparative effectiveness studies, measuring and improving the effectiveness of informed consent in clinical research; improving the quality and efficiency of clinical trial data management; clinical research trials for the prevention or treatment of HIV / AIDS and vaccine clinical trials
Immunologic endpoint determination for experimental vaccines (HIV, pneumococcus, malaria, TB, flu) and
Logistics, operations, quality assurance, and assay validation for immunologic evaluation of vaccines in the clinical trial setting
Research focus includes statistical methods for bioassays (e.g., flow cytometry, sequencing); dynamic modeling of biological systems (e.g., multi-type cell populations, B-cell repertoire); nonparametric methods for supervised and unsupervised learning; stochastic processes (e.g., branching processes); algorithms for scalable data analysis.
Design and analysis of vaccine efficacy trials, genotype-specific vaccine efficacy-based sieve analysis,immune correlates of vaccine protection, analysis of vaccine-induced immune response durability and survival analysis
HIV vaccine development and trial design, combination HIV prevention, mucosal immunology and mucosal sampling design in HIV prevention trials, the intersection of oncology and infectious disease, comparative effectiveness, decision analysis and health-related quality of life
HIV and tuberculosis (Tb) vaccine research and development, human challenge experiments, microbiome modulation of immunity, immune activation—polymicrobial infections, combination HIV prevention, malaria clinical trials/vaccines and molecular epidemiology
Research interests involved developing and implementing clinical trials for HIV vaccines, mucosal sampling in HIV Vaccine trials and cultural/community challenges in implementing Vaccine Trials in Africa
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication strategies, and to use models to capture kinetic features of the human microbiome.
Research is focused on the development of a safe and effective vaccine to combat the spread of HIV and to investigate how HIV infection leads to AIDS. Two major areas of research is to better understand how neutralizing antibodies against HIV are developed during natural HIV-infection,and engineer immunogens that will elicit broadly neutralizing antibody responses against HIV.
Epidemiologic studies of infectious disease transmission, vaccine studies and the development of novel statistical methods and designs for studies of infectious disease transmission. Efficacy and effectiveness assessments of control and prevention strategies for infectious diseases of import to global health, including influenza, cholera, dengue, and tuberculosis
Research interests involve mechanisms driving the differentiation of B cells following vaccination and infection, understanding how differences in the pre-immune repertoire influences immunity and vaccine Development
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.